• Sanofi's overhaul of genomic medicines strategy spells end of Sangamo alliance

    11 days ago - By MedCity News

    A Sanofi strategy shift is leading to the end of a gene-editing alliance with Sangamo Therapeutics. Though the partnership has produced encouraging early clinical data with a sickle cell therapy highly personalized to the patient, Sanofi now plans to focus on universal approaches to genomic medicines.
    Read more ...